• Antibodies to HHV-6 during acute COVID-19 may help predict development of Long COVID

    Autoantibodies directed against neural targets have most predictive power.

  • iciHHV-6B linked to systemic lupus erythematosus (SLE) in Japanese and European populations

    iciHHV-6B, when integrated into chromosome 22q, was strongly associated with SLE and with SLE severity.

  • HHV-6 linked to miscarriage through Mendelian randomization studies

    The findings are consistent with previous studies directly linking HHV-6 endometrial infection to miscarriage.

  • Finnish investigators find unexpected evidence of HHV-6B integration into mitochondrial DNA

    Could HHV-6B infection exacerbate mitochondrial disease?

Newsletter | About Us | Contact Us | Donate | Repository

HHV-6 Foundation | HHV-6 Disease Information for Patients, Clinicians, and Researchers | Apply for a Grant Navigation
  • Home
  • About
    • Scientific Advisory Board
    • Staff
    • Contact Us
    • Donate
  • Patients
    • What Is HHV-6?
    • HHV-6A/B Testing
  • Research
    • Grants
    • Repository
      • Cart
      • Checkout
    • HHV-6A/B Testing
    • List of Genes & Proteins
    • Lab Protocols
    • Pictorial Atlas of HHV-6
    • HHV-6 Antivirals
    • Researcher FAQ
    • Newsletter
  • Home
  • About
    • Scientific Advisory Board
    • Staff
    • Contact Us
    • Donate
  • Patients
    • What Is HHV-6?
    • HHV-6A/B Testing
  • Research
    • Grants
    • Repository
      • Cart
      • Checkout
    • HHV-6A/B Testing
    • List of Genes & Proteins
    • Lab Protocols
    • Pictorial Atlas of HHV-6
    • HHV-6 Antivirals
    • Researcher FAQ
    • Newsletter

Latest Transplant Complications Articles

View Post

German HCT specialists call for iciHHV-6 screening of patients and donors

In All, ciHHV-6, Transplant Complications by Kristin LoomisMarch 30, 2023

Study finds value in HHV-6 testing of other tissues, as well as blood, and of routine testing for iciHHV-6 in both donors and recipients of allo-HCT.

View Post

Herpesvirus reactivation during alloHSCT associated with greatly increased mortality and expense

In All, CNS Disease, Transplant Complications by Kristin LoomisJanuary 9, 2023

Data from 13,363 transplant patients underline the importance of preventing, diagnosing and treating viral reactivation.

View Post

Virus specific T cell infusions show promise for preventing HHV-6B reactivation in transplant patients

In All, Transplant Complications, Treatments - Adoptive T cell, Treatments - Alternative by Kristin LoomisJanuary 9, 2023

Review highlights the importance of cell mediated immunity and the limitations of antivirals, vaccines and immunoglobulin therapy for HHV-6, VZV and HSV.

View Post

Reference values established for virus specific T-cells in healthy adults

In All, Transplant Complications, Treatments - Adoptive T cell, Treatments - Immune Stimulant by Kristin LoomisDecember 5, 2022

These values may help determine the type of treatment transplant patients should receive: antiviral or adoptive T-cell therapy or a reduction in immunosuppression.

View Post

HHV-6 encephalitis following CAR-T cell therapy

In All, Cancer, CNS Disease, Encephalitis & Encephalopathy, Transplant Complications, Treatments - Adoptive T cell by Kristin LoomisDecember 5, 2022

A growing number of case reports reveal reactivation similar to that seen after hematopoietic stem cell therapy. Could CAR-T cells be a source of lytic HHV-6?

View Post

Adding an adoptive NK cell infusion to naïve T-Cell-depleted grafts may reduce the rate of HHV-6B reactivation and encephalitis

In All, Immunity & Immunotherapy, Transplant Complications by Kristin LoomisAugust 15, 2022

A small pediatric study found that adoptive NK cell infusions eliminated HHV-6B encephalitis, while maintaining a low rate of GVHD. At a ratio of NK/CD4 >2, the HHV-6B reactivation rate dropped dramatically.

View Post

HHV-6 found to be the most frequent cause of viremia in children following HSCT

In All, Transplant Complications by Kristin LoomisJuly 12, 2022

A prospective study of children transplanted for both malignant and nonmalignant disease found HHV-6 viremia in 53% of cases.

View Post

Evidence for HHV-6-induced thrombotic microangiopathy in transplant patients undergoing HSCT

In All, Hematological Disorders, Transplant Complications by Kristin LoomisJuly 12, 2022

Among infectious agents, HHV-6 was found to be an independent risk factor for thrombotic microangiopathy (TMA) and only HHV-6 infection was associated with TMA-related mortality.

View Post

Breakthrough reactivation of HHV-6 occurs with liver transplantation in spite of valganciclovir preemptive therapy for CMV

In All, Gastrointestinal, Liver Disease, Transplant Complications by Kristin LoomisMay 20, 2022

High-grade HHV-6 viremia is independently associated with rejection of liver transplants within 12 months

View Post

Adult patients with lower levels of anti-HHV-6 IgG are significantly more likely to experience HHV-6 reactivation following cord blood transplant

In All, Cancer, Hematological Disorders, Transplant Complications by Kristin LoomisMay 20, 2022

Patients with low levels of HHV-6 antibodies might benefit from treatment from IVIG or novel neutralizing antibodies before cord blood transplantation

View Post

Quantitative PCR of serum found superior to whole blood in differentiating between latent virus and viremia following cord blood transplantation

In All, Transplant Complications by Kristin LoomisMay 20, 2022

Use of serum more easily distinguishes viremia from latent virus

View Post

HHV-6 reactivation following haploidentical hematopoietic stem-cell transplant found to predict acute graft versus host disease in China

In All, Cancer, Encephalitis & Encephalopathy, Transplant Complications by Kristin LoomisApril 4, 2022

25% of the patients with HHV-6 reactivation developed aGVHD compared to 18% in those without reactivation.

View Post

Substantial reduction in hippocampal volume found in pediatric hematopoietic stem cell transplant patients with HHV-6B reactivation

In All, Transplant Complications by Kristin LoomisFebruary 1, 2022

Surprisingly, the damage from HHV-6B infection often occurred in the absence of obvious neurological symptoms. Patients without HHV-6 reactivation had no reduction in volume.

View Post

Telomeric integration, excision and subsequent and transmission in people with inherited chromosomally integrated HHV-6B (iciHHV-6B)

In All, ciHHV-6, Transplant Complications by Kristin LoomisJanuary 3, 2022

Exploiting a hypervariable region of the HHV-6B genome, investigators achieve new insights about integration, excision, and genomic stability of iciHHV-6B

View Post

Significantly worse outcomes in critically ill hematology patients associated with HHV-6 infection.

In All, Transplant Complications by Kristin LoomisJanuary 3, 2022

Two reports associate detectable HHV-6 DNA in body fluids with increased risk of mortality in patients being treated for hematologic malignancies.

  • Page 3 of 9
  • ←
  • 1
  • ...
  • 2
  • 3
  • 4
  • ...
  • 9
  • →

Clinical News

  • Alzheimer’s Disease
  • Animal Models
  • Autoimmune Disease
  • Cancer
  • iciHHV-6
  • CNS Disease
  • COVID-19 / HHV-6 Reactivation
  • Drug Hypersensitivity
  • Encephalitis & Encephalopathy
  • Endocrine Conditions
  • Epilepsy and Seizures
  • Gastrointestinal
  • Genes
  • Heart Disease
  • Hematological Disorders
  • HIV/AIDS Progression
  • Immunity & Immunotherapy
  • Infertility & Miscarriage
  • Kidney Disease
  • Liver Disease
  • Lung Disease
  • Lymphadenopathy & Fever
  • ME/CFS
  • Multiple Sclerosis
  • Rash & Roseola
  • Transplant Complications
  • Treatments – Adoptive T cell
  • Treatments – Alternative
  • Treatments – Antiviral
  • Treatments – Immune Stimulant

About HHV-6

  • What Is HHV-6?
  • What is Inherited Chromosomally Integrated HHV-6
  • HHV-6 Repository of Reagents
  • HHV-6A/B Testing
  • HHV-6 Treatment

SUBSCRIBE TO OUR NEWSLETTER

ABOUT THE HHV-6 FOUNDATION

The HHV-6 Foundation in a non-profit entity founded to encourage scientific exchange between investigators and to provide pilot grants for promising scientific and clinical research on the under- appreciated viruses HHV-6A and HHV-6B.

The Foundation sponsors international conferences and supports scientists and clinicians seeking to clarify the role of the two HHV-6 viruses in disease. Since HHV-6A and HHV-6B can smolder in the brain and other organs without circulating in the peripheral blood or plasma, identifying chronic infection is a challenge.

Read More

HHV-6 Foundation | 1482 East Valley Road, Suite 619 | Santa Barbara, CA, 93108 | Toll Free: (888) 530-6726


Copyright ©2004-2022 HHV-6 FOUNDATION


WEB DESIGN AND DEVELOPMENT BY INSTYLE TECHNOLOGIES
  • Home
  • About
  • Conditions
  • Clinicians
  • Testing
  • Research
  • Repository
  • Patients
  • Treatment
  • News & Blog
  • Donate
  • Contact Us
  • Cart
  • Checkout
  • Privacy Policy
  • Terms of Use